• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

高安动脉炎患者急性期反应物、白细胞介素-6、肿瘤坏死因子-α与疾病活动度之间的关联

Association between acute phase reactants, interleukin-6, tumor necrosis factor-α, and disease activity in Takayasu's arteritis patients.

作者信息

Li Jing, Wang Yahong, Wang Yanhong, Wang Ying, Yang Yunjiao, Zhao Jiuliang, Li Mengtao, Tian Xinping, Zeng Xiaofeng

机构信息

Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, 100730, China.

Department of Ultrasound Imaging, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.

出版信息

Arthritis Res Ther. 2020 Dec 10;22(1):285. doi: 10.1186/s13075-020-02365-y.

DOI:10.1186/s13075-020-02365-y
PMID:33303010
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7726865/
Abstract

BACKGROUND

To investigate the association between blood biomarkers and disease activity of Takayasu's arteritis (TAK) in a follow-up cohort.

METHODS

Disease activity was assessed by clinical manifestations and repeated vascular Doppler examinations. The association between erythrocyte sedimentation rate (ESR), serum levels of high-sensitive C-reactive protein (hsCRP), interleukin-6(IL-6), and tumor necrosis factor-α (TNFα) and disease activity were analyzed by logistic regression and survival analysis. Kaplan-Meier method was used to estimate the cumulative remission rate curve, log-rank tests for group comparison, and Cox regression for estimating hazard ratios of these parameters for disease activity.

RESULTS

428 patients were included. 188 patients were in active disease, and 240 patients were in inactive disease at baseline. Elevation of ESR, hsCRP, and IL-6 were associated with active disease at baseline and during follow-up. Cox regression and Kaplan-Meier analysis showed that lower possibility and longer time to remission were associated with elevated ESR (hazard ratio [HR] = 0.32, 80 vs 33 weeks, p < 0.001), hsCRP (HR = 0.45, 70 vs 31 weeks, p < 0.001), and IL-6 (HR = 0.54, 66 vs 34 weeks, p < 0.01) in patients with active disease at baseline, while higher risk and shorter time for relapse were associated with elevated ESR (HR = 2.1, 59 vs 111 weeks, p < 0.001), hsCRP (HR = 2.1, 79 vs 113 weeks, p < 0.001), IL-6 (HR = 2.5, 64 vs 117 weeks, p < 0.001), and TNFα (HR = 2.7, 65 vs 114 weeks, p < 0.001) in patients with inactive disease at baseline.

CONCLUSIONS

Elevated ESR, CRP, and IL-6 are associated with active disease, lower possibility, and longer time to achieve disease remission. Elevation of any among ESR, CRP, IL-6, and TNFα is associated with high risk and short time for relapse during follow-up.

摘要

背景

在一个随访队列中研究血液生物标志物与大动脉炎(TAK)疾病活动度之间的关联。

方法

通过临床表现和重复的血管多普勒检查评估疾病活动度。采用逻辑回归和生存分析来分析红细胞沉降率(ESR)、高敏C反应蛋白(hsCRP)、白细胞介素-6(IL-6)和肿瘤坏死因子-α(TNFα)的血清水平与疾病活动度之间的关联。采用Kaplan-Meier法估计累积缓解率曲线,采用对数秩检验进行组间比较,采用Cox回归估计这些参数对疾病活动度的风险比。

结果

纳入428例患者。188例患者在基线时处于疾病活动期,240例患者在基线时处于疾病非活动期。ESR、hsCRP和IL-6升高与基线时及随访期间的疾病活动有关。Cox回归和Kaplan-Meier分析显示,基线时处于疾病活动期的患者,ESR升高(风险比[HR]=0.32,80周对33周,p<0.001)、hsCRP升高(HR=0.45,70周对31周,p<0.001)和IL-6升高(HR=0.54,66周对34周,p<0.01)与缓解可能性较低和缓解时间较长有关;而基线时处于疾病非活动期的患者,ESR升高(HR=2.1,59周对111周,p<0.001)、hsCRP升高(HR=2.1,79周对113周,p<0.001)、IL-6升高(HR=2.5,64周对117周,p<0.001)和TNFα升高(HR=2.7,65周对114周,p<0.001)与复发风险较高和复发时间较短有关。

结论

ESR、CRP和IL-6升高与疾病活动、缓解可能性较低及缓解时间较长有关。ESR、CRP、IL-6和TNFα中任何一项升高与随访期间复发风险较高和复发时间较短有关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a022/7726865/dc4b1341c659/13075_2020_2365_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a022/7726865/96bc1bf22b3e/13075_2020_2365_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a022/7726865/dc09403f7e41/13075_2020_2365_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a022/7726865/dc4b1341c659/13075_2020_2365_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a022/7726865/96bc1bf22b3e/13075_2020_2365_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a022/7726865/dc09403f7e41/13075_2020_2365_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a022/7726865/dc4b1341c659/13075_2020_2365_Fig3_HTML.jpg

相似文献

1
Association between acute phase reactants, interleukin-6, tumor necrosis factor-α, and disease activity in Takayasu's arteritis patients.高安动脉炎患者急性期反应物、白细胞介素-6、肿瘤坏死因子-α与疾病活动度之间的关联
Arthritis Res Ther. 2020 Dec 10;22(1):285. doi: 10.1186/s13075-020-02365-y.
2
Laboratory investigations useful in giant cell arteritis and Takayasu's arteritis.对巨细胞动脉炎和高安动脉炎有用的实验室检查。
Clin Exp Rheumatol. 2003 Nov-Dec;21(6 Suppl 32):S23-8.
3
Serum cytokine profiles in Takayasu's arteritis: search for biomarkers.大动脉炎患者的血清细胞因子谱:寻找生物标志物。
Clin Exp Rheumatol. 2015 Mar-Apr;33(2 Suppl 89):S-32-5. Epub 2014 Dec 1.
4
The role of plateletcrit in Takayasu arteritis: A potential biomarker for disease activity and 6-month treatment response.血小板比容在多发性大动脉炎中的作用:疾病活动和 6 个月治疗反应的潜在生物标志物。
Int J Rheum Dis. 2023 Dec;26(12):2517-2525. doi: 10.1111/1756-185X.14951. Epub 2023 Oct 24.
5
Elevated serum 25-hydroxyvitamin D: a potential indicator of remission in Takayasu arteritis patients with normal ESR and CRP levels.血清25-羟维生素D升高:红细胞沉降率和C反应蛋白水平正常的大动脉炎患者缓解的潜在指标。
Clin Rheumatol. 2024 Jun;43(6):1979-1987. doi: 10.1007/s10067-024-06957-w. Epub 2024 Apr 10.
6
The study of novel inflammatory markers in takayasu arteritis and its correlation with disease activity.探讨大动脉炎新型炎症标志物及其与疾病活动的相关性。
Indian Heart J. 2021 Sep-Oct;73(5):640-643. doi: 10.1016/j.ihj.2021.08.002. Epub 2021 Aug 13.
7
Value of acute-phase reactants in monitoring disease activity and treatment response in idiopathic retroperitoneal fibrosis.急相反应物在特发性腹膜后纤维化疾病活动监测和治疗反应中的价值。
Nephrol Dial Transplant. 2012 Jul;27(7):2819-25. doi: 10.1093/ndt/gfr779. Epub 2012 Jan 23.
8
Analysis of predictive factors for treatment resistance and disease relapse in Takayasu's arteritis.分析川崎病治疗抵抗和疾病复发的预测因素。
Clin Rheumatol. 2018 Oct;37(10):2789-2795. doi: 10.1007/s10067-018-4094-2. Epub 2018 Apr 23.
9
Tumor necrosis factor alpha inhibitors in patients with Takayasu's arteritis refractory to standard immunosuppressive treatment: cases series and review of the literature.肿瘤坏死因子-α抑制剂治疗对标准免疫抑制治疗抵抗的多发性大动脉炎患者:病例系列研究和文献复习。
Clin Rheumatol. 2013 Dec;32(12):1827-32. doi: 10.1007/s10067-013-2380-6. Epub 2013 Sep 1.
10
(18)F-Fluorodeoxyglucose positron emission tomography and serum cytokines and matrix metalloproteinases in the assessment of disease activity in Takayasu's arteritis.(18)氟脱氧葡萄糖正电子发射断层扫描与血清细胞因子及基质金属蛋白酶在大动脉炎疾病活动度评估中的应用
Rev Bras Reumatol Engl Ed. 2016 Jul-Aug;56(4):299-308. doi: 10.1016/j.rbre.2015.08.007. Epub 2015 Sep 9.

引用本文的文献

1
Assessment of Coronary Microvascular Dysfunction in Patients with Systemic Vasculitis.系统性血管炎患者冠状动脉微血管功能障碍的评估
Curr Cardiol Rep. 2025 Apr 8;27(1):81. doi: 10.1007/s11886-025-02231-w.
2
A rare case of Takayasu arteritis with aortic dissection in a young male patient presented with hypertensive urgency.一名年轻男性患者出现高血压急症,这是一例罕见的伴有主动脉夹层的高安动脉炎病例。
Ann Med Surg (Lond). 2025 Jan 31;87(2):1069-1073. doi: 10.1097/MS9.0000000000002960. eCollection 2025 Feb.
3
Real-World Biomarkers for Pediatric Takayasu Arteritis.

本文引用的文献

1
2018 Update of the EULAR recommendations for the management of large vessel vasculitis.2018 年版 EULAR 大血管血管炎管理建议更新。
Ann Rheum Dis. 2020 Jan;79(1):19-30. doi: 10.1136/annrheumdis-2019-215672. Epub 2019 Jul 3.
2
Are cytokines and chemokines suitable biomarkers for Takayasu arteritis?细胞因子和趋化因子是否适合作为 Takayasu 动脉炎的生物标志物?
Autoimmun Rev. 2017 Oct;16(10):1071-1078. doi: 10.1016/j.autrev.2017.07.023. Epub 2017 Aug 2.
3
Long-Term Outcomes and Prognostic Factors of Complications in Takayasu Arteritis: A Multicenter Study of 318 Patients.
真实世界生物标志物在儿科大动脉炎中的应用。
Int J Mol Sci. 2024 Jul 4;25(13):7345. doi: 10.3390/ijms25137345.
4
Clinical Characteristics and Outcomes of Aortic Arch Emergencies: Takayasu Disease, Fibromuscular Dysplasia, and Aortic Arch Pathologies: A Retrospective Study and Review of the Literature.主动脉弓急症的临床特征与预后:大动脉炎、纤维肌性发育异常及主动脉弓病变:一项回顾性研究及文献综述
Biomedicines. 2023 Aug 6;11(8):2207. doi: 10.3390/biomedicines11082207.
5
Outcome Measures and Biomarkers for Disease Assessment in Takayasu Arteritis.大动脉炎疾病评估的结局指标和生物标志物
Diagnostics (Basel). 2022 Oct 21;12(10):2565. doi: 10.3390/diagnostics12102565.
6
Giant cell arteritis versus Takayasu's Arteritis: Two sides of the same coin?巨细胞动脉炎与高安动脉炎:同一硬币的两面?
Saudi J Ophthalmol. 2022 Apr 18;35(3):198-203. doi: 10.4103/SJOPT.SJOPT_152_21. eCollection 2021 Jul-Sep.
7
Administration of mesenchymal stem cells in diabetic kidney disease: mechanisms, signaling pathways, and preclinical evidence.间充质干细胞在糖尿病肾病中的应用:机制、信号通路和临床前证据。
Mol Cell Biochem. 2022 Aug;477(8):2073-2092. doi: 10.1007/s11010-022-04421-4. Epub 2022 Apr 25.
8
Immunomodulatory Properties and Osteogenic Activity of Polyetheretherketone Coated with Titanate Nanonetwork Structures.具有钛纳米网络结构涂层的聚醚醚酮的免疫调节性能和成骨活性。
Int J Mol Sci. 2022 Jan 6;23(2):612. doi: 10.3390/ijms23020612.
9
New-Onset Ulcerative Colitis in a Young Caucasian Woman with Unclassified Arteritis.一名患有未分类动脉炎的年轻白种女性新发溃疡性结肠炎。
Case Rep Vasc Med. 2022 Jan 7;2022:7773222. doi: 10.1155/2022/7773222. eCollection 2022.
10
Using the co-expression network of T cell-activation-related genes to assess the disease activity in Takayasu's arteritis patients.利用 T 细胞激活相关基因的共表达网络评估大动脉炎患者的疾病活动度。
Arthritis Res Ther. 2021 Dec 16;23(1):303. doi: 10.1186/s13075-021-02636-2.
大动脉炎并发症的长期预后和预测因素:一项 318 例患者的多中心研究。
Circulation. 2017 Sep 19;136(12):1114-1122. doi: 10.1161/CIRCULATIONAHA.116.027094. Epub 2017 Jul 12.
4
Profiles of serum cytokine levels in Takayasu arteritis patients: Potential utility as biomarkers for monitoring disease activity.大动脉炎患者血清细胞因子水平概况:作为监测疾病活动生物标志物的潜在效用。
J Cardiol. 2017 Sep;70(3):278-285. doi: 10.1016/j.jjcc.2016.10.016. Epub 2016 Dec 15.
5
Development and initial validation of the Indian Takayasu Clinical Activity Score (ITAS2010).印度大动脉炎临床活动评分(ITAS2010)的制定与初步验证。
Rheumatology (Oxford). 2013 Oct;52(10):1795-801. doi: 10.1093/rheumatology/ket128. Epub 2013 Apr 16.
6
Diagnosis and assessment of Takayasu arteritis by multiple biomarkers.通过多种生物标志物诊断和评估大动脉炎。
Circ J. 2013;77(2):477-83. doi: 10.1253/circj.cj-12-0131. Epub 2012 Oct 26.
7
Assessment of disease activity and progression in Takayasu's arteritis.大动脉炎疾病活动度和进展的评估。
Clin Exp Rheumatol. 2011 Jan-Feb;29(1 Suppl 64):S86-91. Epub 2011 May 11.
8
Takayasu arteritis--advances in diagnosis and management.Takayasu 动脉炎——诊断和治疗的进展。
Nat Rev Rheumatol. 2010 Jul;6(7):406-15. doi: 10.1038/nrrheum.2010.82.
9
Assessment of disease activity and progression in Takayasu's arteritis with Disease Extent Index-Takayasu.大动脉炎疾病严重度指数-大动脉炎评估大动脉炎的疾病活动度和进展。
Rheumatology (Oxford). 2010 Oct;49(10):1889-93. doi: 10.1093/rheumatology/keq171. Epub 2010 Jun 11.
10
Modification and validation of the Birmingham Vasculitis Activity Score (version 3).伯明翰血管炎活动评分(第3版)的修订与验证
Ann Rheum Dis. 2009 Dec;68(12):1827-32. doi: 10.1136/ard.2008.101279. Epub 2008 Dec 3.